Related references
Note: Only part of the references are listed.Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
Erik R. Dubberke et al.
INFECTIOUS DISEASES AND THERAPY (2023)
The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
Robert Orenstein
INFECTIOUS DISEASES AND THERAPY (2023)
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection A Randomized Clinical Trial
Thomas Louie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection & nbsp;A Phase 3, Open-Label, Single-Arm Trial
Matthew D. Sims et al.
JAMA NETWORK OPEN (2023)
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
Paul Feuerstadt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
Robert Orenstein et al.
BMC INFECTIOUS DISEASES (2022)
Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers
Melissa Dsouza et al.
CELL HOST & MICROBE (2022)
730. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection
Pablo C Okhuysen et al.
Open Forum Infectious Diseases (2022)
Gut metabolites predict Clostridioides difficile recurrence
Jennifer J. Dawkins et al.
MICROBIOME (2022)
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
Sahil Khanna et al.
DRUGS (2022)
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
Sahil Khanna et al.
ANTIBIOTICS-BASEL (2022)
The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection
Anna Maria Seekatz et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
Barbara H. McGovern et al.
CLINICAL INFECTIOUS DISEASES (2021)
RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
Sahil Khanna et al.
CLINICAL INFECTIOUS DISEASES (2021)
S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial
Sahil Khanna et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)
Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis
Raseen Tariq et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)
Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
S. Khanna
JOURNAL OF INTERNAL MEDICINE (2021)
The Bacterial Gut Microbiota of Adult Patients Infected, Colonized or Noncolonized by Clostridioides difficile
Monique J. T. Crobach et al.
MICROORGANISMS (2020)
Metabolomic networks connect host-microbiome processes to human Clostridioides difficile infections
John Robinson et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota After Vancomycin (vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV)
Dmitri Bobilev et al.
Open Forum Infectious Diseases (2019)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
L. Clifford McDonald et al.
CLINICAL INFECTIOUS DISEASES (2018)
Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
Cheleste M. Thorpe et al.
PLOS ONE (2018)
Recovery of gut microbiota of healthy adults following antibiotic exposure
Albert Palleja et al.
NATURE MICROBIOLOGY (2018)
The evolution of the host microbiome as an ecosystem on a leash
Kevin R. Foster et al.
NATURE (2017)
Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection
M. N. Quraishi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
Robert Orenstein et al.
CLINICAL INFECTIOUS DISEASES (2016)
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection
Sahil Khanna et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Burden of Clostridium difficile Infection in the United States
Fernanda C. Lessa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The vocabulary of microbiome research: a proposal
Julian R. Marchesi et al.
MICROBIOME (2015)
The Roles of Clostridium difficile and Norovirus Among Gastroenteritis-Associated Deaths in the United States, 1999-2007
Aron J. Hall et al.
CLINICAL INFECTIOUS DISEASES (2012)